Accelerating the export of innovative drugs and consolidating the foundation for internationalization

Recently, a number of domestic innovative drugs have been approved overseas. At the same time, a number of pharmaceutical companies have reached overseas authorizations for their products. The pace of domestic innovative drugs "going overseas" has accelerated. Industry insiders believe that "going overseas" in the field of biomedicine is one of the important main lines in the future. Opening up overseas markets is a reflection of the international competitiveness of related enterprises, which are expected to obtain higher valuations.

A number of innovative drugs have been approved overseas

Recently, three domestic innovative drugs have been approved overseas. On November 8, U.S. time, CHMED'S FRUZAQLA (FRUQUINTINIB) RECEIVED APPROVAL FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR THE TREATMENT OF TREATMENT-TREATED METASTATIC COLORECTAL CANCER.

Junshi Biosciences announced at the end of October that the biologics license application for toripalimab was approved by the U.S. Food and Drug Administration. The approved indication is for toripalimab in combination with cisplatin/gemcitabine as first-line treatment for adult patients with metastatic or recurrent locally advanced nasopharyngeal carcinoma and as a monotherapy for adult patients with recurrent, unresectable or metastatic nasopharyngeal carcinoma whose disease has progressed on or after prior platinum-based therapy.

In addition, Yifan Pharma said that the license application for the biologics of ibergostim α injection was approved by the FDA, and the company will use ACROTECH's rich sales experience and perfect sales network in the field of innovative tumor patented drugs to quickly open the market of ibergostim α injection in the United States, and improve the influence and market share of ibergostim α injection in the global market.

Junshi Biosciences said that the company has reached commercialization cooperation with overseas partners in more than 50 countries on toripalimab, and the internationalization process of toripalimab will be accelerated in the future.

Overseas licensing transactions are active

国产创新药Overseas licensing transactions are active，11月以来多个产品达成海外授权。

On November 20, Haisco announced that it had reached an agreement with ChiesiFarmaceutici S.p.A. of Italy to license the rights and interests of a class of new drug HSK31858 tablets with independent intellectual property rights outside Greater China (including Hong Kong, Macao and Taiwan) to Chiesi for a fee. On November 13, Legend Biotech and Novartis Pharmaceuticals entered into a collaboration under which Novartis will acquire the exclusive global rights to Legend Biotech's chimeric antigen receptor T cell (CAR-T) therapy targeting DLL3.

In addition, related products of Hengrui Pharmaceutical, Fosun Pharma and Hansoh Pharmaceutical have recently achieved overseas licensing.

Essence Securities said that in the future, the popularity of overseas licensing transactions will continue, and the foundation for the internationalization of innovative drugs will continue to be consolidated. China Merchants Securities believes that the R&D quality of domestic innovative drug companies is constantly improving, and the targets and molecular forms authorized by pharmaceutical companies overseas are diversified.

"Going global" is an important strategic direction for the development of China's innovative drug enterprises. China Merchants Securities believes that "going overseas" in the field of biomedicine is one of the important main lines in the future, and the overseas market is a blue ocean waiting to be opened. According to Shenwan's three-level industry classification, the top indicators of the average proportion of overseas revenue are medical R&D and production outsourcing, medical consumables, APIs, medical equipment, diagnostic services, and in vitro diagnostics.

From the perspective of the development process of the domestic innovative drug industry, the project research and development of China's innovative drug companies has undergone a transformation from "rapid follow-up" to attaching importance to the global vision. Huaan Securities believes that the main force of innovative pharmaceutical companies has entered the stage of product sales volume, and biotechnology companies have entered the stage of commercialization capability competition from the past pursuit of new targets and differentiated indications. We look forward to improving access to more valuable medicines and benefiting more patients.

Source: China Economic Net